Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine.
Tumor as source of tumor associated antigens (TAA) and sentinel lymph node (SLN) configure the first interaction between the malignant disease and the patient's immune system. As consequence of this interaction, a local immune response is elicited inside the SLN. Tumor's cytokines reach the SLN conditioning its cellular microenvironment to produce local permissive immune responses. This local tolerogenic immunity is decisional because it starts a systemic also permissive immunity. The tumor progresses.To counteract this mechanism, we have designed a medical procedure to create an immunotherapeutic site (ITS) that reproduces, distantly from the tumor, a TAA source and a draining lymph node but with a cellular microenvironment conditioned to promote local protective instead of permissive immune responses. Due to ITS decisional role, this local protective immunity starts a systemic anti-tumoral immune response.In progressive ovarian cancer, we tested an ITS using the autologous thermostable hemoderivative-cancer vaccine as TAA source and granulocyte macrophage-colony stimulant factor plus etoposide, injected both at the vaccination site, as conditioner of the draining lymph node cellularity. The immunophenotyping of lymph node cell populations showed that ITS acquired a locally protective immune profile T-regulatory-cells/activated-antigen presenting-cells and systemically increased the antiprogressive effect of the tested vaccine.
Lasalvia-Prisco
Eduardo
E
PharmaBlood Inc, Department of Research and Development, North Miami Beach, Florida, USA;
Garcia-Giralt
Emilio
E
Cucchi
Silvia
S
Vázquez
Jesús
J
Robinson
Leonard
L
Dalton
John
J
Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60
12750554
Int J Cancer. 1991 Feb 20;47(4):626-32
1995491
Cancer Res. 1999 Oct 15;59(20):5160-8
10537292
Clin Exp Immunol. 1991 Jun;84(3):383-8
1828396
Clin Immunol Immunopathol. 1990 Jan;54(1):161-5
2152858
Vaccine. 2005 Apr 22;23(22):2909-21
15780740
J Immunol. 2004 Jul 15;173(2):1444-53
15240741
Am J Pathol. 2005 Nov;167(5):1301-7
16251414
Ann N Y Acad Sci. 1993 Mar 20;677:404-6
8494226
J Immunother. 1999 Mar;22(2):166-74
10093041
Cancer Res. 1992 May 1;52(9):2440-6
1568214
Immunology. 2003 Nov;110(3):304-12
14632657
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Med Oncol. 2006;23(1):91-104
16645234
Int J Immunopharmacol. 1990;12(1):77-88
2303320
Cancer Res. 2003 Oct 15;63(20):6956-61
14583497
Blood. 1996 Jul 1;88(1):202-10
8704175
Invest New Drugs. 1984;2(2):221-5
6332093
Cancer. 2000 Jul 15;89(2):236-41
10918150
Immunol Rev. 2002 Oct;188:147-54
12445288
Am J Pathol. 2002 Jul;161(1):19-26
12107085
J Clin Oncol. 1984 Mar;2(3):187-93
6699671
Cancer Immunol Immunother. 1989;28(2):131-5
2917364
Scand J Immunol. 1986 May;23(5):605-9
2939555
Breast Cancer Res Treat. 2006 Nov;100(2):149-60
16819567
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
J Nucl Med. 2002 Jun;43(6):811-27
12050328
Nat Rev Immunol. 2006 Sep;6(9):659-70
16932751